Differential Effects of Drugs Targeting Cancer Stem Cell (CSC) and Non-CSC Populations on Lung Primary Tumors and Metastasis

Cancer stem cells (CSCs) are thought to be responsible for tumor initiation and recurrence after chemotherapy. Targeting CSCs and non-CSCs with specific compounds may be an effective approach to reduce lung cancer growth and metastasis. The aim of this study was to investigate the effect of salinomycin, a selective inhibitor of CSCs, with or without combination with paclitaxel, in a metastatic model. To evaluate the effect of these drugs in metastasis and tumor microenvironment we took advantage of the immunocompetent and highly metastatic LLC mouse model. Aldefluor assays were used to analyze the ALDH+/− populations in murine LLC and human H460 and H1299 lung cancer cells. Salinomycin reduced the proportion of ALDH+ CSCs in LLC cells, whereas paclitaxel increased such population. The same effect was observed for the H460 and H1299 cell lines. Salinomycin reduced the tumorsphere formation capacity of LLC by more than 7-fold, but paclitaxel showed no effect. In in vivo experiments, paclitaxel reduced primary tumor volume but increased the number of metastatic nodules (p<0.05), whereas salinomycin had no effect on primary tumors but reduced lung metastasis (p<0.05). Combination of both drugs did not improve the effect of single therapies. ALDH1A1, SOX2, CXCR4 and SDF-1 mRNA levels were higher in metastatic lesions than in primary tumors, and were significantly elevated in both locations by paclitaxel treatment. On the contrary, such levels were reduced (or in some cases did not change) when mice were administered with salinomycin. The number of F4/80+ and CD11b+ cells was also reduced upon administration of both drugs, but particularly in metastasis. These results show that salinomycin targets ALDH+ lung CSCs, which has important therapeutic effects in vivo by reducing metastatic lesions. In contrast, paclitaxel (although reducing primary tumor growth) promotes the selection of ALDH+ cells that likely modify the lung microenvironment to foster metastasis.

[1]  T. Taguchi,et al.  Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers , 2009, Clinical Cancer Research.

[2]  A. Calvo,et al.  Inhibition of telomerase activity preferentially targets aldehyde dehydrogenase-positive cancer stem-like cells in lung cancer , 2011, Molecular Cancer.

[3]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[4]  Lakshmaiah Sreerama,et al.  ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors. , 2008, Lung cancer.

[5]  Anna E. Lokshin,et al.  Drug-Selected Human Lung Cancer Stem Cells: Cytokine Network, Tumorigenic and Metastatic Properties , 2008, PloS one.

[6]  J. Ji,et al.  Salinomycin can effectively kill ALDH(high) stem-like cells on gastric cancer. , 2011, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[7]  A. Jemal,et al.  Cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.

[8]  Patrick W. Lee,et al.  Aldehyde Dehydrogenase Activity of Breast Cancer Stem Cells Is Primarily Due To Isoform ALDH1A3 and Its Expression Is Predictive of Metastasis , 2011, Stem cells.

[9]  Laura A. Sullivan,et al.  Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. , 2010, Cancer research.

[10]  C. Brennan,et al.  Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. , 2010, Cell stem cell.

[11]  F. Bertucci,et al.  Aldehyde Dehydrogenase 1–Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer , 2009, Clinical Cancer Research.

[12]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[13]  Alexei A. Sharov,et al.  Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells , 2007, Nature Cell Biology.

[14]  M. Serio,et al.  The critical role of SDF-1/CXCR4 axis in cancer and cancer stem cells metastasis , 2008, Journal of endocrinological investigation.

[15]  G. Sica,et al.  CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. , 2009, The Journal of thoracic and cardiovascular surgery.

[16]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[17]  J. Massagué,et al.  Beyond tumorigenesis: cancer stem cells in metastasis , 2007, Cell Research.

[18]  G. Opelz,et al.  Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. , 2009, Biochemical and biophysical research communications.

[19]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[20]  L. Vermeulen,et al.  Cancer stem cell niche: the place to be. , 2011, Cancer research.

[21]  A. Bikfalvi,et al.  Tumor angiogenesis , 2020, Advances in cancer research.

[22]  Eleonora Petrucci,et al.  The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. , 2010, Blood cells, molecules & diseases.

[23]  M. Uhlén,et al.  CXCR4 and cancer , 2010, Pathology international.

[24]  A. Albini,et al.  Metastasis signatures: genes regulating tumor–microenvironment interactions predict metastatic behavior , 2007, Cancer and Metastasis Reviews.

[25]  R. Salgia,et al.  The role of chemokine receptor CXCR4 in lung cancer , 2010, Cancer biology & therapy.

[26]  F. Greco,et al.  Paclitaxel-based combination chemotherapy in advanced non-small cell lung cancer. , 2001, Lung cancer.

[27]  H. Itamochi,et al.  Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin. , 2011, Gynecologic oncology.

[28]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[29]  Yi Wang.  Effects of salinomycin on cancer stem cell in human lung adenocarcinoma A549 cells. , 2011, Medicinal chemistry (Shariqah (United Arab Emirates)).

[30]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[31]  Feng Jiang,et al.  Aldehyde Dehydrogenase 1 Is a Tumor Stem Cell-Associated Marker in Lung Cancer , 2009, Molecular Cancer Research.

[32]  R. Weinberg,et al.  Phenotypic plasticity and epithelial‐mesenchymal transitions in cancer and normal stem cells? , 2011, International journal of cancer.

[33]  Bethan Psaila,et al.  The metastatic niche: adapting the foreign soil , 2009, Nature Reviews Cancer.

[34]  A. Peled,et al.  Potential of CXCR4 antagonists for the treatment of metastatic lung cancer , 2011, Expert review of anticancer therapy.

[35]  R. Weinberg,et al.  Cell plasticity and heterogeneity in cancer. , 2013, Clinical chemistry.

[36]  R. Kerbel,et al.  Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. , 2009, Cancer research.

[37]  Graeme I Murray,et al.  Current and emerging concepts in tumour metastasis , 2010, The Journal of pathology.

[38]  T. Voloshin,et al.  Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice. , 2011, Cancer research.

[39]  O. Kallioniemi,et al.  Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress , 2012, British Journal of Cancer.

[40]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[41]  J. Nolta,et al.  Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. , 2006, Blood.

[42]  T. Kang,et al.  Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells. , 2011, Cancer letters.

[43]  Eric S. Lander,et al.  Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.

[44]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.